|
September 2005
(v05-n09) |
|
- Main Story - Cypress
Bioscience (CYPB)
- pgs. 1-13
- Macro Market Commentary
- pgs. 14-15
- Research Director Commentary
- pgs. 16-19
- BSR
Coverage Update - pg.
20-30
- Biotech Sector Short Interest Report
- (coming soon!)
- BSR
Model Portfolio - pg. 31
- (Full outline below...)
|
 |
|
|
This month's Biotech Monthly
Main Story is unusual in that it is more of a cautionary tale than the
typical debut of coverage. In this issue, we discuss the potential of
Cypress Bioscience (CYPB). Just as we were completing this issue,
Cypress announced a pivotal Phase III trial barely failed to reach its
primary endpoints. |
 |
|
| Because of the failure, this
issue serves to highlight the dangers peculiar to investing in companies
who seek to treat disorders of the central nervous system. If you have a
preference for this sub-sector, this issue is worth a read. |
Subscriber direct access |
|
| The following is an outline of this issue of
Biotech Monthly. |
|
|
- Main Story -
Cypress Bioscience
- Disclosures
- Investment case
- Introduction
- Table: Cypress Bioscience
milestones
-
Fibromyalgia syndrome
- Table: Major concurrent
symptoms
- Why antidepressants?
- Why tricyclics?
- Why not tricyclics?
-
- Why
something like milnacipran?
- The basis for using milnacipran
-
- Lead
drug setup
- Table: Milnacipran development
path at Cypress
- Forest Labs deal
- Phase II results
- Table: Phase II results
- Initial pivotal trial design
- Table: Pivotal trial composite
endpoints
- Unique features of the Phase
III program
- First Phase III trial: Top
line results
- Table: Results summary
-
Competitive landscape
- Tricyclic antidepressants
- Sidebar: Receptor binding affinity
- Table: Comparative side effect
profiles
- Other SNRI antidepressants
- Table: Side effect comparison
venlafaxine/milnacipran/placebo
- Other treatments
-
-
Obstructive sleep apnea
What can go wrong
- Macro Market Commentary - "Caution
& conservatism"
-
- Research Director's Commentary -
"Statistically speaking, of course"
Biotech Monthly Coverage Updates
- Genta
- Adolor
- OBD-OIC
- Other stuff
- Investment case
- BioMarin
- Dendreon
- trp-p8
- Neuvenge
- ID Biomedical
- Better mousetrap
- Thimerosol free
- Bad luck
- Distribution price weakness
- BLA filing delays
- Summary
- Investment case
- Introgen
- Sonus
- Important correction
- Onyx pharma
- Investment case
- Discovery Labs
- Investment case
- Forbes Medi-Tech
- Oncolytics Biotech
- Indevus
- Nabi
- Other news
- Investment Case
- Targeted Genetics
- Investment case
- Valentis
- Investment case
- Medarex
- Biotech Sector Short Interest
- Chart: NASDAQ Biotech Index (NBI)
short interest (indexed)
- Chart: NBI short interest as a
percentage of total NASDAQ short interest
- Table: Top 15 NBI short interest as a
percentage of float
BSR Model Portfolio Performance |
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
